The pharmaco-economics of peri-operative statin therapy.
We analysed the pharmaco-economics of the prospective peri-operative studies of statin administration for major elective vascular surgery, using the NHS reference costs for 2004. This analysis suggests that peri-operative statin therapy for patients undergoing vascular surgery may present the most cost-effective use of statin therapy yet described, with a number-needed-to-treat of 15 and almost 60% of the total cost of atorvastatin therapy recovered through a reduction in peri-operative adverse events.
Biccard
B M
BM
Nuffield Department of Anaesthetics, University of Oxford, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK. bruce.biccard@nda.ox.ac.uk
Sear
J W
JW
Foëx
P
P
D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D016903:Drug Monitoring / Q000191:economics; D006538:Heptanoic Acids / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D019990:Perioperative Care / Q000191:economics* / Q000379:methods; D011446:Prospective Studies; D011758:Pyrroles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D013222:State Medicine / Q000191:economics; D006113:United Kingdom; D014656:Vascular Surgical Procedures / Q000191:economics*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin